<div id="readability-page-1">Investor Martin Shkreli’s big biotech short position is blowing up after the stock’s monumental rally over the past week, following a major clinical catalyst. Popularly known as “Pharma bro,” Shkreli initiated a short position against California-based Capricor Therapeutics Inc. ( CAPR ) two weeks ago, referring to the company’s HOPE-3 cell therapy for Duchenne Muscular Dystrophy as “COPE-3.” “It will not work. This is the company's only asset,” Shkreli said, yet the company cleared a major regulatory hurdle last week, with results showing “strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy.” See Also: 10 Health Care Stocks With Whale Alerts In Today’s Session This led to a monumental rally in the stock, with its Momentum scores in Benzinga’s Edge Rankings following suit with a sharp spike over the course of the past week. <h2>Biotech Stock’s Momentum Score Spikes</h2> The Momentum score in Benzinga’s Edge Stock Rankings is assessed based on a stock’s price movements and volatility across multiple time frames, before being ranked as a percentile against all other stocks. A surge in a stock’s Momentum score is often indicative of a big uptick in volumes, volatility and the share price, often a result of a major news or fundamental catalyst. <h3>Capricor Therapeutics</h3> Following the positive results of its phase-3 HOPE-3 trial evaluating Deramiocel to treat Duchenne Muscular Dystrophy, the stock soared 440% within just one day, destroying Shkreli’s short position, which was expecting the stock to settle at around $2 per share. Shkreli has responded by criticizing the data, accusing the company’s CEO, Linda Marban, of lying and giving the results a positive spin. The stock’s momentum score has nonetheness witnessed a steep surge, rising from 3.83 to 96.4 within the span of a week, following its strong rally. Besides this, the stock has a favorable price trend in the short, medium and long terms. Click here for deeper insights into the company, its products and operations. &lt;figure class=&#34;wp-block-image aligncenter size-full&#34;&gt;<img width="728" height="110" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/08041502/Screenshot-2025-12-08-at-2.44.23-PM.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/08041502/Screenshot-2025-12-08-at-2.44.23-PM.png"/>&lt;/figure&gt; Read More: <ul> <li>Best Biotech Penny Stocks</li> </ul> Photo courtesy: Shutterstock</div>

CAPR

Martin Shkreli's short position against Capricor Therapeutics Inc. is failing as the stock soared 440% following positive phase-3 trial results for its HOPE-3 cell therapy. The stock's Momentum score spiked from 3.83 to 96.4, indicating increased volatility and share price. Shkreli criticized the data, accusing the CEO of misrepresenting results. The stock's favorable price trend continues across short, medium, and long terms.

Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes